Abstract:Transcriptional enhanced associate domain (TEAD) proteins are the downstream effectors of the Hippo signaling pathway that regulate cell proliferation and stem cell functions. The expression of TEAD family is upregulated in many cancer types including pancreatic, colorectal, breast, and prostate cancers, which is correlated with poor survival in patients. Pharmacologic modulators of TEADs could therefore find application in cancer treatment and regenerative medicine. In this presentation, we report our exploration of the TEAD2 Yap-binding domain conformational ensemble and its binding interaction characteristics with peptides and small molecules, using both molecular dynamics simulation and experimental binding studies with FP probes. We carried a series of conventional, cosolvent, and Gaussian-biased MD studies and discovered that the binding subsites II and III possess considerable flexibility as the free energy calculations indicate that multiple low-energy states exist with only about 1.4 Kcal/mol barriers among them. Together with the binding results, our study points to additional “hot spots”/pharmacophores for fresh design of novel small-molecule inhibitors disrupting YAP/TEAD protein-protein interactions. Note: This abstract was not presented at the conference. Citation Format: Yiping Li, Wei Zhou, Chenglong Li. Computational insights on the druggability of TEAD YAP-binding domain [abstract]. In: Proceedings of the AACR Special Conference on the Hippo Pathway: Signaling, Cancer, and Beyond; 2019 May 8-11; San Diego, CA. Philadelphia (PA): AACR; Mol Cancer Res 2020;18(8_Suppl):Abstract nr B11.

Abstract B11: Computational Insights on the Druggability of TEAD YAP-binding Domain